Previous Pause Next
Home >> News Center >>
Enterprise & Industry
Gates Foundation Eyes Novartis AG Head Of Global R&D PDF Print E-mail
Thursday, 15 September 2011 00:58
The Gates Foundation, belonging to Microsoft founder Bill Gates and his wife Melinda, could poach Novartis's head of global development, a Swiss newspaper reported on Sunday, citing two sources.
BioSante Pharmaceuticals, Inc. Successfully Completes LibiGel(R) Pharmacokinetic Study PDF Print E-mail
Thursday, 15 September 2011 00:00
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), today announced successful completion of its principal LibiGel (testosterone gel) pharmacokinetic (PK) study. The top-line results indicate that LibiGel increases levels of free testosterone, bioavailable testosterone and total testosterone in the serum of postmenopausal women to within the normal ranges for younger, premenopausal women.
GlaxoSmithKline Stops Tykerb Arm of Breast-Cancer Trial PDF Print E-mail
Wednesday, 14 September 2011 00:49
GlaxoSmithKline PLC  said it will stop administering breast cancer drug Tykerb alone to patients in a clinical trial, after an independent committee decided the medicine would probably produce worse results than Roche Holding AG's (ROG.VX) rival product Herceptin.
Sucampo Pharmaceuticals, Inc. and Numab Sign Drug Discovery Collaboration PDF Print E-mail
Tuesday, 13 September 2011 00:52
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP - News), an international pharmaceutical company, and Numab AG today announced that Sucampo’s wholly owned subsidiary, Sucampo AG, and Numab AG, have entered into a research and development collaboration that provides Sucampo with access to Numab’s proprietary technology for the discovery of high-affinity antibodies against certain selected targets.
The National Institute for Clinical Excellence (NICE) Questions Merck & Co., Inc. , Nycomed COPD Drug PDF Print E-mail
Tuesday, 13 September 2011 00:40
More research is needed to assess the effectiveness of Daxas, a new lung drug developed by Nycomed and marketed in Europe by U.D. group Merck & Co, Britain's health cost watchdog said on Friday.
FDA Panel Gives Nod to Bayer HealthCare /Johnson & Johnson Anti-clot Drug PDF Print E-mail
Monday, 12 September 2011 00:35
Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) announced today that the U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended approval of rivaroxaban, a novel, once-daily, oral anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF).
Furiex Pharmaceuticals, Inc. Reports Positive Phase 2 Results for MuDelta in Treatment of Diarrhea-Predominant Irritable Bowel Syndrome PDF Print E-mail
Saturday, 10 September 2011 00:59
Furiex Pharmaceuticals, Inc. (Nasdaq:FURX - News) today announced successful results from its Phase II proof-of-concept clinical trial evaluating the safety and efficacy of MuDelta, an investigational oral agent for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). IBS-D is a common functional bowel disorder that causes chronic diarrhea and abdominal pain.
Syndax Pharmaceuticals Inc. Drug Shows Survival Benefits in Phase 2 Breast Cancer Trial PDF Print E-mail
Saturday, 10 September 2011 00:01
Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced today that ENCORE 301, a randomized, placebo-controlled phase 2 study of exemestane with and without entinostat hit its primary endpoint of an improvement in progression-free survival (PFS).
Eisai Inc. Unveils Risk-Sharing Approach to Accelerate Phase 3 Studies PDF Print E-mail
Friday, 09 September 2011 00:54

Eisai has announced a new partnership with SFJ Pharmaceuticals designed to accelerate its late-stage clinical development activities.

Merck Sues Kentucky For Outsourcing Vioxx Suit PDF Print E-mail
Thursday, 08 September 2011 00:56
Outsourcing is all the rage these days and some state attorneys general are no exception. Take the sprawling Vioxx litigation. More than one state attorney general has retained an outside law firm to help with efforts to recover money from Merck for allegedly defrauding the public over the heart risks associated with the painkiller, which was withdrawn in 2004.
Curis, Inc. (CRIS) Partner Genentech Sends Cancer Drug to FDA PDF Print E-mail
Thursday, 15 September 2011 00:56
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company has submitted a New Drug Application for vismodegib to the U.S. Food and Drug Administration (FDA) for the treatment of people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.
Warner Chilcott, PLC, Merck & Co., Inc. Bone Drugs Need Label Changes on Use Duration, Panel Says PDF Print E-mail
Wednesday, 14 September 2011 00:51
U.S. health advisers declined to suggest how long women should take a class of drugs used by millions to prevent bone fractures, but agreed the labels should be changed to reflect uncertainty about the risks and benefits of long-term use.
High Hopes for Gilead Sciences, Inc.'s "Quad" Studies as Company Eyes Foster City Expansion PDF Print E-mail
Wednesday, 14 September 2011 00:46
Gilead Sciences Inc's (GILD.O) experimental four-drug HIV pill may need to do more than simply match the safety and effectiveness of existing therapies to meet its lofty sales expectations.
Novartis Corporation Med Gets EU OK for Benign Brain Tumors PDF Print E-mail
Tuesday, 13 September 2011 00:50

Novartis announced that the European Commission (EC) has approved Votubia (everolimus) tablets for the treatment of patients aged 3 years and older, with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC), who require therapeutic intervention but are not amenable to surgery.

Panmira and FLAP LLC Spun Out of Amira Pharmaceuticals, Inc. PDF Print E-mail
Monday, 12 September 2011 00:37
Panmira Pharmaceuticals, LLC and FLAP, LLC, today announced their formation around certain assets spun out immediately preceding the acquisition of Amira Pharmaceuticals, Inc. (Amira) by Bristol-Myers Squibb Company (NYSE: BMY).
Dendreon Corporation to Cut 500 Jobs; COO Resigns PDF Print E-mail
Monday, 12 September 2011 00:29
Dendreon Corporation (NASDAQ:DNDN - News) today announced restructuring plans, overall cost reductions, and an update on PROVENGE® (sipuleucel-T) sales.
Ardea Biosciences, Inc. Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad PDF Print E-mail
Saturday, 10 September 2011 00:03
Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that it has completed formal End-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA) and successfully reached agreement on the following key aspects of its proposed lesinurad Phase 3 development plan
Auxilium Pharmaceuticals Announces Positive Top-Line Results from XIAFLEX(R) Multi-Cord Study PDF Print E-mail
Friday, 09 September 2011 00:56
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced positive top-line results from a pilot clinical study to assess safety, tolerability, and multiple-dose pharmacokinetics of XIAFLEX® (collagenase clostridium histolyticum) in adult Dupuytren's contracture subjects with multiple palpable cords.
AstraZeneca PLC Pushes for R&D Makeover PDF Print E-mail
Friday, 09 September 2011 00:45
AstraZeneca's president of research and development has outlined the importance of the company's newly refocused business strategy to its future success.
DiaGenic ASA: Grant of Australian Family 3 patent PDF Print E-mail
Thursday, 08 September 2011 00:54

The Australian family 3 patent application (2005250219) has now been granted. The claims allowed cover the use of some important gene sequences in blood sample for detection of cancer, among others, breast cancer. The patent will be valid until 2023.

<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 8 of 127